We are submitting the Copy of the unabridged Annual Report, for the financial year ended 31.03.2025.
BALPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bal Pharma Limited has submitted its unabridged Annual Report for the financial year ended 31 March 2025 to the stock exchanges, along with the notice for its 38th Annual General Meeting scheduled for 25 September 2025 via video conferencing. The AGM agenda includes adopting the audited financial statements, declaring a dividend of Re. 1.20 per equity share (face value Rs. 10), appointing Secretarial Auditor Mr. Parameshwar G Bhat for 5 years, reappointing Mr. Jatish Sheth as Independent Director for a second term, ratifying Cost Auditor remuneration of Rs. 40,000 for FY 2025-26, and approving a new Employee Stock Option Plan 2025 covering up to 10 lakh equity shares. The company operates 6 manufacturing plants across Karnataka, Maharashtra, Uttarakhand and Rajasthan, with Unit 3 (Parenterals) currently marked as temporarily non-operational.
The Rs. 1.20 per share dividend signals continued shareholder returns, while the proposed ESOP 2025 (up to 10 lakh shares) could lead to mild dilution if fully exercised. Retail shareholders should review the full Annual Report for detailed financial performance and note that the AGM is being held virtually with e-voting from 22-24 September 2025.